JOLYN HOLLIDAY VEZA: Open Payments
NPI 1871848770 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,406 in 178 payments from 40 companies in 2025. Trend: 2023 $3,660 · 2024 $4,492 · 2025 $4,406
Food & beverage: $3,219Long term medical supply or device loan: $1,000Education: $188
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 33 | $1,324 |
| Gilead Sciences, Inc. | 8 | $239 |
| PFIZER INC. | 12 | $222 |
| Janssen Biotech, Inc. | 10 | $221 |
| Exelixis Inc. | 10 | $218 |
| Merck Sharp & Dohme LLC | 10 | $210 |
| Daiichi Sankyo Inc. | 10 | $205 |
| Eisai Inc. | 9 | $185 |
| AstraZeneca Pharmaceuticals LP | 9 | $174 |
| ABBVIE INC. | 5 | $114 |
Products named: KISQALI, CABOMETYX, Trodelvy, Enhertu, KEYTRUDA, Lenvima, REBLOZYL, VENCLEXTA.
Industry payments across IN — which companies pay providers there.
